Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.

Nov 8, 2024 · For once, cardiologists find good news in the US Centers for Medicare & Medicaid Services (CMS) annual Hospital Outpatient Prospective Payment System (HOPPS) final rule: in 2025 the payment rate for coronary computed tomography angiography (CCTA) will double.

Oct 30, 2024 · WASHINGTON, DC—As a guide for deciding whether to revascularize patients with intermediate coronary stenoses, quantitative flow ratio (QFR) isn’t able to match fractional flow reserve (FFR) in terms of 12-month clinical outcomes, data from the large, randomized, FAVOR III Europe trial show.

Jan 1, 2025 · Large, practice-changing clinical trials—those presented at the big cardiology meetings—made up half of our most-read stories. But the other contenders in 2024 reflect more quotidian concerns of TCTMD readers, relating to issues they hear about from patients or that are changing the way they practice medicine.

Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released by Eli Lilly on Wednesday.

Oct 10, 2024 · LISBON, Portugal—One of the first presentations at Europe’s annual cardiothoracic surgery conference was not about a new technique or device, but whether the revolutionary obesity medications targeting the glucagon-like peptide-1 (GLP-1) receptor will change the landscape of surgical practice.

Oct 28, 2024 · Disclosures. EARLY TAVR was sponsored by Edwards Lifesciences. Généreux reports consulting for and/or receiving speaking fees from Abbott Vascular, Abiomed, Boston Scientific, Caranx Medical, Cardiovascular System Inc, Edwards Lifesciences, GE Healthcare, iRhythm Technologies, Medtronic, OpSens, Pi-Cardiac, Puzzle Medical, Saranas, Shockwave, Siemens, Soundbite Medical Inc, Teleflex, and 4C ...

Mar 6, 2024 · Photo Credit: Adapted from Brown K. TCT 564: A new perspective: intracardiac echocardiographic guidance for the implantation of a left atrial appendage occluder device (Watchman) with a leadless pacemaker (Micra).